Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand

INTRODUCTION: Efavirenz (EFV) is commonly used for first‐line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed adults has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Phongsamart, Wanatpreeya, Jantarabenjakul, Watsamon, Chantaratin, Sasitorn, Anugulruengkitt, Suvaporn, Suntarattiwong, Piyarat, Sirikutt, Pakpen, Kosalaraksa, Pope, Maleesatharn, Alan, Chokephaibulkit, Kulkanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743364/
https://www.ncbi.nlm.nih.gov/pubmed/35001501
http://dx.doi.org/10.1002/jia2.25862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743364/
https://www.ncbi.nlm.nih.gov/pubmed/35001501
http://dx.doi.org/10.1002/jia2.25862

Ejemplares similares